Scientists find possible artefacts of oldest known Wallacean hominids in Indonesia
Archaeologists from Australia and Indonesia found the small, chipped tools, used to cut little animals and carve rocks, under the soil in the region of Soppeng in South Sulawesi. Radioactive tracing of these tools and the teeth of animals found around the site were dated at up to 1.48 million years ago.
The findings could transform theories of early human migrations, according to an article the archaeologists published in the journal Nature in August.
The earliest Wallacean humans, pre-historic persons known as Homo Erectus, were thought to have only settled in Indonesia's Flores island and Philippines' Luzon island around 1.02 million years ago, as they were thought to be incapable of distant sea travel, proving the significance of the Sulawesi findings in theories of migration.
'These were artefacts made by ancient humans who lived on the earth long before the evolution of our species, Homo Sapiens,' said Adam Brumm, lead archaeologist from Griffith University in Queensland, Australia.
'We think Homo Erectus somehow got from the Asian mainland across a significant ocean gap to this island, Sulawesi, at least 1 million years ago," Brumm said.
Wallacea is a region in Eastern Indonesia including several islands such as Sulawesi, Lombok, Flores, Timor, Sumbawa that lie between Borneo and Java and Australia and New Guinea. The region is named for the naturalist Alfred Russel Wallace who studied the fauna and flora of the area.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Fiery meteor sighting leaves onlookers in awe across Australia
A meteor caused widespread awe across Australia as people across the state of Victoria captured it falling to earth. Onlookers were left stunned when a bright object appeared to fall from the sky and hit the ground with a bang on Sunday (10 August). Footage from CCTV and dashcams shows the glowing object lighting up the nighttime sky, shocking onlookers. Scientists later confirmed that the flash was indeed a meteor, and the bang could have been a sonic boom - a loud noise created when an object travels through the air faster than the speed of sound.
Telegraph
4 hours ago
- Telegraph
Being stalked raises women's risk of heart disease
Stalking raises the risk of heart disease for women and should be added to risk factors alongside smoking and bad diet, scientists have warned. Harvard University discovered that women who were stalked were 41 per cent more likely to suffer from cardiovascular disease, which can cause heart attacks and strokes. For those forced to obtain a restraining order, the risk rose to 70 per cent. One in five women and one in 11 men have been a victim of stalking, according to data from the Crime Survey for England and Wales. Although stalking is known to cause fear and trigger mental health problems, the new study is the first to show it has an impact on heart health. 'To many people, stalking doesn't seem to be such a serious experience, as it often does not involve physical contact. But stalking has profound psychological consequences that can have physical implications,' said senior author Dr Karestan Koenen, professor of psychiatric epidemiology at Harvard TH Chan School of Public Health. 'Our study highlights that these preventable, common, non-contact forms of violence against women are health hazards and need to be considered as such, just like we consider smoking or poor diet.' Stalking is defined as linked incidents causing distress, fear or alarm, which can involve obscene, threatening unwanted letters, text messages or phone calls, being watched or followed or having people loiter near to the home or workplace. The crime survey estimated there were more than 129,000 stalking offences last year. For the new study researchers looked at the cardiovascular outcomes for 66,270 women, aged between 36 and 56 who were enroled in the Nurses' Health Study II between 2001 and 2021. Around 12 per cent reported that they had been stalked while just over five per cent said they had obtained a restraining order. Researchers found a clear link between cardiovascular disease and stalking. Women whose medical records confirmed heart attacks or strokes were more likely to have reported being stalked or obtaining a restraining order. Experts believe stalking may cause psychological distress, which can disrupt the nervous system, impair proper blood vessel function, and negatively affect other biological mechanisms. Many stressful life experiences are known to increase the risk of cardiovascular disease, such as the loss of a loved one or bankruptcy, but it is the first research to link it to stalking. Dr Rebecca Lawn, a research associate in epidemiology at Harvard, said: 'Stalking is often seen as a form of violence that does not involve physical contact, which may make it seem less serious. 'However, our findings suggest stalking should not be minimised. Stalking can be chronic, and women often report making significant changes in response such as moving. 'Perhaps because it is our nature to re-think about things that happen to us, making us experience the situation over and over.' Dr Harmony Reynolds, former chair of American Heart Association's Clinical Cardiology & Stroke Women's Health Science Committee, added: 'While this study shows a more moderate risk, given the long-time frame, it highlights how feeling unsafe can affect the body, in addition to the mind.' The research was published in the journal Circulation.
The Sun
4 hours ago
- The Sun
‘Remarkable' new vaccine shown to slow down world's deadliest cancer in move to ‘beat cancer for everyone'
THOUSANDS of Brits with cancer have been given fresh hope as a new jab could slow down the disease and boost survival. The vaccine, described as "remarkable" by scientists, has shown promising results in the fight against one of the deadliest forms of the disease - pancreatic cancer. Early trials have proven the jab's ability to supercharge the immune system, enabling it to attack cancer cells and potentially prolong life for patients. More trials are now underway among a larger group of pancreatic and bowel cancer patients, as experts warn it is "too early" to say whether the jab will work at scale. Pancreatic cancer, which affects around 10,000 Brits each year, is the deadliest cancer in the world. And only about seven out of 100 of them will survive it for five years or more, according to Cancer Research UK. This is partly because it shows no symptoms until it has already spread to other parts of the body, making it incredibly hard to treat. While surgery, chemotherapy and radiation can help extend life, they rarely offer a cure. But researchers are now optimistic that this new vaccine could change that, providing a vital new treatment option other therapies fall short. 'Our results show that in the group of patients who had profound immune responses 68 per cent) we saw longer survival than we have expected in this cancer,' said Dr Zev Wainberg, study lead from the University of California, Los Angeles. 'Quite a remarkable finding to occur in a phase 1 trial.' The jab targets a mutated gene called KRAS, which is found in many pancreatic and bowel cancers. I'm a doctor, NEVER ignore these pancreatic cancer symptoms It's a type of immunotherapy vaccine designed to improve the immune system's ability to fight cancer by delivering the vaccine directly to the lymph nodes, which play a crucial role in immune defence. In the phase 1 trial, 20 pancreatic cancer patients and five bowel cancer patients received the vaccine. After 20 months, 68 per cent of patients developed strong immune responses. On average, the pancreatic cancer patients survived around two years and five months after receiving the vaccine, according to the study published in Nature Medicine. 'Patients with the strongest immune responses lived longer and stayed cancer-free for more than 15 months,' Dr Zev added. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This "off-the-shelf" version means that it can be manufactured in bulk and given more rapidly. Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said: 'This study is a big step forward in treating pancreatic cancer. "The 'off-the-shelf' vaccine approach is quicker, cheaper, and could help many more people.' The study has already led to a phase 2 trial with 144 pancreatic and bowel cancer patients, with results expected in the coming months. Dr Dani Edmunds, research information manager at Cancer Research UK, added: "Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. "Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. "The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. "These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. "Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. "More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone." Dr Magnus Dillon, an oncologist at The Royal Marsden NHS Foundation Trust, said: "It's extremely promising to have a vaccine that seems to stimulate T cell activity in KRAS-driven tumours – these are generally 'immune cold', so therapies which stimulate immune responses in this group of patients are much needed. 'Many patients have these KRAS mutations, so an off-the-shelf vaccine could benefit lots of people – it saves the cost and time required to make a personalised vaccine. 'However, it's a bit early to definitively tell whether this will work to prevent cancer relapse in this group of patients who have had all disease removed at surgery - larger studies will be needed. "A bigger challenge is to see if the activated immune system could also work against established tumours, which have many ways to avoid immune attack and prevent immune cells from entering.'
